Attralus

Executive Summary

Attralus is a private biotechnology company based in South San Francisco, dedicated to developing transformative therapeutics for amyloidosis by targeting amyloid removal. Founded in 2020, the company focuses on biologics and RNA/gene therapies to address the unmet needs of patients with systemic amyloidosis, a group of rare and progressive diseases characterized by abnormal protein deposits. Attralus is currently in the Phase 1/2 clinical stage, advancing its lead candidate through early human trials. The company's mission-driven approach aims to not only halt disease progression but also reverse organ damage by clearing amyloid fibrils. Despite being in early stages, Attralus has the potential to address a significant market gap, as existing therapies primarily focus on reducing amyloid precursor production. The company's platform technology could offer a novel mechanism of action, positioning it as a unique player in the amyloidosis space. However, as a private entity with limited public information, the risk profile is elevated, and success hinges on clinical data and securing additional funding.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 interim data readout for lead asset50% success
• Q1 2027Initiation of Phase 2 trial for second indication60% success
• 2026Series C financing or partnership announcement70% success